PECAM‐1, a key player in neuroinflammation
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Platelet endothelial cell adhesion molecule‐1 (PECAM‐1, CD31) is a 130‐kDa protein, which plays a significant role in the adhesion cascade. It is therefore involved in leucocyte endothelium interaction and in leucocyte transendothelial migration during inflammation. As neuroinflammation and subsequent blood brain barrier disruption are integral processes in many neurological disorders, PECAM‐1 and its soluble form (sPECAM‐1) have been investigated in a number of conditions, rising hopes as a potential marker of disease activity, a possible target in treatment and a prognostic factor. It has been shown that serum and CSF levels of PECAM‐1 and sPECAM‐1 are increased in patients in active stages of multiple sclerosis. Similarly, they rise in individuals after ischaemic stroke. PECAM‐1 has also been shown to be involved in the pathogenesis of A β‐related cerebral vascular disorders, such as Alzheimer disease. It participates in the pathomechanism of paraneoplastic neurological disorders and in neuroinflammation in NeuroAIDS. A number of experiments on animal models were carried out in order to investigate PECAM‐1 role in the above‐mentioned conditions and more, including brain trauma and nerve root injury. In this review most recent investigations on PECAM‐1 biology and its role in neuroinflammation have been described and discussed from a multidisciplinary point of view.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giri, R., Shen, Y., Stins, M., Du Yan, S., Schmidt, A. M., Stern, D., Kim, K.-S., Zlokovic, B., & Kalra, V. K. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.6.c1772 · Cited by 218
Kuenz, B., Lutterotti, A., Khalil, M., Ehling, R., Gneiss, C., Deisenhammer, F., Reindl, M., & Berger, T. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.06.019 · Cited by 70 · cited 1×
“[33], who observed in their cohort study that sPECAM-1 was increased during an acute relapse and in remission compared with progression.”
Background
Cited by
PECAM-1: A Multi-Functional Molecule in Inflammation and Vascular Biology
Woodfin, A., Voisin, M.-B., & Nourshargh, S. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.151456 · Cited by 583
Shan, S., Zhang, Y., Zhao, H., Zeng, T., & Zhao, X. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.134261 · Cited by 506
Ceulemans, A.-G., Zgavc, T., Kooijman, R., Hachimi-Idrissi, S., Sarre, S., & Michotte, Y. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-74 · Cited by 351
“In patients, VCAM-1 was increased up to 5 days after symptom onset while ICAM-2 and PECAM-1 were not increased after injury [123,124].”
BackgroundInfluentialWalker, D. G., Dalsing-Hernandez, J. E., Campbell, N. A., & Lue, L.-F. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2008.09.003 · Cited by 267
Neuroinflammation and Cerebrovascular Disease in Old Age: A Translational Medicine Perspective
Di Napoli, M., & Shah, I. M. (2011) · Journal of Aging Research · doi:10.4061/2011/857484 · Cited by 263
Metadata
- Authors
- Kalinowska, A., & Losy, J.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2006-11-13
- Volume
- 13
- Issue
- 12
- Pages
- 1284-1290
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W1971836810
- Cited by
- 90
- References
- 2
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PECAM‐1, a key player in neuroinflammation. https://app.cochat.ai/papers/10.1111/j.1468-1331.2006.01640.x
- The paper
- Kalinowska, A., & Losy, J. (2006). PECAM‐1, a key player in neuroinflammation. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2006.01640.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.